Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1993-8-26
|
| pubmed:abstractText |
Human breast and pancreatic adenocarcinomas are tumors of ductal epithelial cell origin and as such produce and express on their surface polymorphic epithelial cell mucin encoded by the MUC 1 gene. We have previously reported that tumor-specific cytotoxic T cells derived from patients bearing such tumors recognize specific epitopes on the mucin polypeptide core. This recognition was not MHC-restricted because of the highly repetitive sequence of the polypeptide core, which allows simultaneous recognition of many identical epitopes, and cross-linking and aggregation of TCR on mucin-specific T cells. Those studies were performed with limited numbers of tumor cells or allogeneic tumor cell lines. A renewable source of autologous cells presenting this Ag was necessary to further explore mucin-specific immunity. We report here successful establishment and functional analysis of mucin-specific CTL lines and clones derived from breast and pancreatic cancer patients, using either autologous or allogeneic mucin-transfected B cells as Ag. Our results demonstrate that transfection of autologous or allogeneic B cells with mucin confers upon them tumor Ag-presenting ability as well as susceptibility to lysis by mucin-specific CTL. Transfection of APC with this or any other human tumor Ag that may be molecularly defined in the future provides a unique and powerful tool with which to examine the ability of a tumor-associated Ag to stimulate T cell responses.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
151
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1654-62
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8393050-Adenocarcinoma,
pubmed-meshheading:8393050-Amino Acid Sequence,
pubmed-meshheading:8393050-Antigen-Presenting Cells,
pubmed-meshheading:8393050-Antigens, Neoplasm,
pubmed-meshheading:8393050-B-Lymphocytes,
pubmed-meshheading:8393050-Breast Neoplasms,
pubmed-meshheading:8393050-Cell Transformation, Viral,
pubmed-meshheading:8393050-Clone Cells,
pubmed-meshheading:8393050-Cloning, Molecular,
pubmed-meshheading:8393050-Cytotoxicity, Immunologic,
pubmed-meshheading:8393050-Herpesvirus 4, Human,
pubmed-meshheading:8393050-Humans,
pubmed-meshheading:8393050-Immunity, Cellular,
pubmed-meshheading:8393050-Molecular Sequence Data,
pubmed-meshheading:8393050-Mucins,
pubmed-meshheading:8393050-Pancreatic Neoplasms,
pubmed-meshheading:8393050-Peptides,
pubmed-meshheading:8393050-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:8393050-Transfection
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.
|
| pubmed:affiliation |
Department of Immunology, Duke University Medical Center, Durham, NC 27710.
|
| pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|